Tamotsu Sagawa

Sapporo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 27, 2026

Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.

Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.

Journal: Journal of gastrointestinal cancer

Published: June 27, 2026

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.

Journal: Journal of gastrointestinal cancer

Published: June 21, 2026

Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report.

Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report.

Journal: Journal of gastrointestinal cancer

Published: May 27, 2026

Oligoprogression in Advanced Gastric and Gastroesophageal Junction Cancer: Integrating Local Therapy, Systemic Treatment Continuation, and Biomarker Reassessment.

Oligoprogression in Advanced Gastric and Gastroesophageal Junction Cancer: Integrating Local Therapy, Systemic Treatment Continuation, and Biomarker Reassessment.

Journal: Journal of gastrointestinal cancer

Published: May 22, 2026

Redefining First-Line HER2-Positive Advanced Gastric Cancer: From Trastuzumab-Based Chemoimmunotherapy to Zanidatamab and Next-Generation HER2 Targeting.

Redefining First-Line HER2-Positive Advanced Gastric Cancer: From Trastuzumab-Based Chemoimmunotherapy to Zanidatamab and Next-Generation HER2 Targeting.

Journal: Journal of gastrointestinal cancer

Published: May 21, 2026

HER2-Targeted Therapy for Metastatic Colorectal Cancer: Current Evidence, Patient Selection, and Practical Treatment Sequencing.

HER2-Targeted Therapy for Metastatic Colorectal Cancer: Current Evidence, Patient Selection, and Practical Treatment Sequencing.

Journal: Journal of gastrointestinal cancer

Published: May 17, 2026

Treatment Selection Beyond Second Line in Metastatic Colorectal Cancer: Practical Sequencing of Cytotoxic Salvage Therapy, Anti-angiogenic Agents, Rechallenge Strategies, and Biomarker-Guided Treatments.

Treatment Selection Beyond Second Line in Metastatic Colorectal Cancer: Practical Sequencing of Cytotoxic Salvage Therapy, Anti-angiogenic Agents, Rechallenge Strategies, and Biomarker-Guided Treatments.

Journal: Journal of gastrointestinal cancer

Published: May 06, 2026

Chemotherapy After Immune Checkpoint Inhibitor Exposure in Advanced Gastric Cancer: Clinical Evidence and Treatment Sequencing in the ICI Era.

Chemotherapy After Immune Checkpoint Inhibitor Exposure in Advanced Gastric Cancer: Clinical Evidence and Treatment Sequencing in the ICI Era.

Journal: Journal of gastrointestinal cancer

Published: May 05, 2026

Beyond Zolbetuximab: Next-Generation Targeting Strategies for CLDN18.2.

Beyond Zolbetuximab: Next-Generation Targeting Strategies for CLDN18.2.

Journal: Journal of gastrointestinal cancer

Published: May 02, 2026

BRAF V600E-Mutated Metastatic Colorectal Cancer: Practical Management in the Post-BREAKWATER Era.

BRAF V600E-Mutated Metastatic Colorectal Cancer: Practical Management in the Post-BREAKWATER Era.

Journal: Journal of gastrointestinal cancer

Published: April 13, 2026

Beyond Sidedness: DNA Methylation as a Biomarker to Refine Anti-EGFR Treatment Selection in RAS/BRAF Wild-type Metastatic Colorectal Cancer.

Beyond Sidedness: DNA Methylation as a Biomarker to Refine Anti-EGFR Treatment Selection in RAS/BRAF Wild-type Metastatic Colorectal Cancer.

Journal: Journal of gastrointestinal cancer

Published: April 10, 2026

Showing 1-12 of 57

Last Updated: 09/26/2026